Investigational fibroblast growth factor receptor 2 antagonists in early phase clinical trials to treat solid tumors

Wang, D; Yang, L; Yu, WN; Zhang, Y

Zhang, Y (reprint author), Zhengzhou Univ, Biotherapy Ctr, Affiliated Hosp 1, Zhengzhou 450052, Henan, Peoples R China.

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019; 28 (10): 903

Abstract

Introduction: Fibroblast growth factor receptor 2 (FGFR2) is a highly conserved transmembrane tyrosine kinase receptor. FGFR2 dysregulation occurs in ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索